Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for IDYA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 -155.93M
March 31, 2026 118.95M
December 31, 2025 -97.53M
September 30, 2025 41.77M
June 30, 2025 45.92M
March 31, 2025 79.82M
December 31, 2024 -197.11M
September 30, 2024 -20.04M
June 30, 2024 68.56M
March 31, 2024 -353.97M
December 31, 2023 -111.94M
September 30, 2023 51.35M
June 30, 2023 -121.38M
March 31, 2023 23.52M
December 31, 2022 -10.28M
September 30, 2022 -18.68M
June 30, 2022 13.32M
Date Value
March 31, 2022 -17.76M
December 31, 2021 -0.413M
September 30, 2021 -56.31M
June 30, 2021 -49.38M
March 31, 2021 36.44M
December 31, 2020 -4.554M
September 30, 2020 -183.58M
June 30, 2020 30.99M
March 31, 2020 10.91M
December 31, 2019 3.887M
September 30, 2019 -38.44M
June 30, 2019 11.41M
March 31, 2019 25.41M
December 31, 2018 6.576M
September 30, 2018 5.261M
June 30, 2018 -14.52M
March 31, 2018 -60.49M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Xencor, Inc. 85.12M
UroGen Pharma Ltd. 1.185M
MeiraGTx Holdings Plc -23.63M
ACADIA Pharmaceuticals, Inc. -8.529M
Alnylam Pharmaceuticals, Inc. -363.46M